BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $87 from $86 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target lowered to $61 from $69 at UBS
- Knight Therapeutics announces launch of Minjuvi in Mexico
- Incyte price target lowered to $65 from $69 at Morgan Stanley
- Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation
- Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue